Literature DB >> 32026467

Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma.

D Ahn1, G J Lee1, J H Sohn1.   

Abstract

BACKGROUND: This study evaluated the incidence, patterns and risk factors for recurrence after hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma (PTC), and verified the predictive role of the risk staging systems in current use.
METHODS: The clinicopathological characteristics and risk categories were analysed according to recurrence in patients who underwent hemithyroidectomy for low- and intermediate-risk conventional PTC, and were followed up for at least 24 months. Five risk staging systems were used to stratify risk: the 2015 American Thyroid Association (ATA) system; Age, Metastases, Extent and Size (AMES) system; Metastases, Age, Complete resection, Invasion and Size (MACIS) system; Grade, Age, Metastases, Extent and Size (GAMES) system; and the eighth AJCC system.
RESULTS: The study included 561 patients; 93·9 per cent of the study population (527 of 561) had a papillary thyroid microcarcinoma 1 cm or smaller in size. At a mean follow-up of 83 months, 25 patients (4·5 per cent) had recurrence; among these patients, 23 (92%) presented with a remaining thyroid lobe. Multifocality was significantly associated with recurrence in univariable and multivariable analyses (adjusted hazard ratio 3·16, 95 per cent c.i. 1·25 to 7·98; P = 0·015). Disease-free survival (DFS) varied according to multifocality (P = 0·010). The five risk staging systems were not associated with recurrence, and their Harrell's C-index ranged from 0·500 to 0·531. DFS rates did not differ between the risk categories in each system.
CONCLUSION: Although the recurrence rate after hemithyroidectomy in patients with low- and intermediate-risk PTC was low, meticulous follow-up focusing on the remaining thyroid lobe is needed for early detection and timely management of recurrence. The risk scoring systems in current use have no predictive role in these patients.
© 2020 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Year:  2020        PMID: 32026467     DOI: 10.1002/bjs.11430

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

1.  Serum Linkage-Specific Sialylation Changes Are Potential Biomarkers for Monitoring and Predicting the Recurrence of Papillary Thyroid Cancer Following Thyroidectomy.

Authors:  Zhen Cao; Zejian Zhang; Rui Liu; Mengwei Wu; Zepeng Li; Xiequn Xu; Ziwen Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-29       Impact factor: 6.055

2.  Clinicopathological Findings Associated With Cervical Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Retrospective Study in China.

Authors:  Yimeng Shi; Zheyu Yang; Yu Heng; Huijun Ju; Yu Pan; Yifan Zhang
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

3.  Clinicopathological and ultrasound features as risk stratification predictors of clinical and pathological nodal status in papillary thyroid carcinoma: a study of 748 patients.

Authors:  Cui Zhang; Baojun Li; Lei Zhang; Fengjiao Chen; Yanhua Zhang; Wen Cheng
Journal:  BMC Cancer       Date:  2022-04-01       Impact factor: 4.430

4.  Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.

Authors:  Mengli Guo; Zhen Chen; Yayi Li; Sijin Li; Fei Shen; Xiaoxiong Gan; Jianhua Feng; Wensong Cai; Qingzhi Liu; Bo Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-23       Impact factor: 5.555

5.  Clinical Relevance and Management of Recurrent Laryngeal Nerve Inlet Zone Lymph Nodes Metastasis in Papillary Thyroid Cancer.

Authors:  Guibin Zheng; Guochang Wu; Haiqing Sun; Chi Ma; Yawen Guo; Dongmin Wei; Wenbin Yu; Haitao Zheng; Xicheng Song
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-22       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.